Aims Despite intensive lipid-lowering therapy, individuals with atherosclerotic cardiovascular disease (ASCVD) exhibit residual inflammatory risk, which drives recurrent cardiovascular events. This ...

Nephrology Times board members Joel Topf, MD, and Anna Gaddy, MD, met at American Society of Nephrology (ASN) Kidney Week 2025 in Houston to discuss day 1's highlights.

As editors for the diabetes and metabolic disorders section of EHJ, we have picked out a few papers published in 2024 that capture the major advances and t

Heart failure is the final outcome of most cardiovascular diseases and shares risk factors with other cardiovascular pathologies. Among these, inflammation plays a central role in disease progression ...

Nature Reviews Endocrinology, Published online: 16 May 2025; doi:10.1038/s41574-025-01133-9The inflammatory spark: how TNF rewrote the insulin resistance narrative

Aims Diabetes mellitus remains a prevalent condition worldwide and a significant risk factor for atherosclerotic cardiovascular disease. Recent evidence suggests the use of glucose-lowering therapie.....

Scientific Reports - mTOR Inhibition limits LPS induced acute kidney injury and ameliorates hallmarks of cellular senescence

Aims Diabetes mellitus remains a prevalent condition worldwide and a significant risk factor for atherosclerotic cardiovascular disease. Recent evidence suggests the use of glucose-lowering therapie.....

The gut-microbiota-derived aromatic amino acid metabolite 4-hydroxyphenylacetic acid (4HPAA) and its analogues have been shown to protect against obesity. In mice, 4HPAA exerts anti-obesogenic effects...

Browse through a range of inspiring news stories from the University of Lincoln, featuring leading research, campus events, and student and alumni success stories.

Browse through a range of inspiring news stories from the University of Lincoln, featuring leading research, campus events, and student and alumni success stories.

Fatty liver disease exacerbates atherosclerosis, but the underlying mechanisms remain unclear. Here, the authors show that D-dopachrome tautomerase (D-DT/MIF-2) acts as an atypical chemokine, promotin...

The data highlight the possibility of SGLT 1/2 inhibitors having protective effects beyond heart failure and diabetes.

Sotagliflozin reduced MACE, with independent reductions in myocardial infarction and stroke, among patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk. The ischae...

YouTube video by Journal of Clinical Investigation

A study examined the effect of gout on cardiovascular disease and mortality risk in patients with type 2 diabetes and whether chronic kidney disease could modify that association.

Amber Simmonds, 29, has lived with hereditary polycystic kidney disease (PKD) since she was 13.

Semaglutide reduces albuminuria and the risk of kidney disease progression in patients with type 2 diabetes and chronic kidney disease (CKD). We conducted a randomized placebo-controlled double-blind ...

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.